TG Therapeutics, Inc. (TGTX)

TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025.

Advantage Alpha Capital Partners LP lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 30.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,314 shares of the biopharmaceutical company's stock after selling 6,274 shares during the

Creative Planning lessened its stake in TG Therapeutics, Inc. (NASDAQ: TGTX) by 8.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 80,753 shares of the biopharmaceutical company's stock after selling 7,534 shares during the quarter. Creative Planning owned approximately 0.05% of TG Therapeutics worth

TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations, slowing growth of Briumvi and concerns about increased competition in the multiple sclerosis market have weighted on its share price. Novartis is testing a less frequently administered version of Kesimpta and Roche's fenebrutinib has generated positive phase 3 results in relapsing multiple sclerosis.

TGTX has seen rapid enrolment of the ENHANCE study which could allow a simplified dosing regime of IV Briumvi. A readout is possible for mid-2026. Investors may need to wait longer for the subcutaneous formulation of Briumvi to become available, with a readout from clinical work possible in late 2026 or early 2027. Kyverna Therapeutics's KYV-101 is emerging as a potential competitor to TGTX's Azer-cel in Multiple Sclerosis, although initial KYV-101 data is from a handful of patients.

Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.

TG Therapeutics, Inc. reported strong Q3 results, with Briumvi revenues up 84% year-over-year and full-year guidance raised to $585 million. TGTX continues to expand Briumvi's market presence, driven by clinical data, increased prescriber adoption, and a growing anti-CD20 MS therapy market. A subcutaneous version of Briumvi is in Phase 3 trials, potentially doubling TGTX's market opportunity if approved and launched by 2028.

TG Therapeutics, Inc. ( TGTX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO & President Adam Waldman - Chief Commercialization Officer Sean Power - CFO, Corporate Secretary & Treasurer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division William Wood - B.

TG Therapeutics (NASDAQ: TGTX - Get Free Report) is expected to announce its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect TG Therapeutics to post earnings of $0.24 per share and revenue of $152.1150 million for the quarter. TG Therapeutics has set its FY 2025 guidance at EPS.Individuals can find conference

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing schedule for IV BRIUMVI® (ublituximab-xiiy), the company's novel, glycoengineered, anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS). The primary endpoint of this trial is non inferior exposure with respect to area under the curve (AUC) at week 16.

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment